

5 November 2025

Sydney, Australia

Cleansing Statement

Nyrada Inc (ASX:NYR), a clinical-stage biotechnology company developing Transient Receptor Potential Canonical (TRPC) ion channel inhibitors to treat a range of medical conditions, today announces the issue of:

- (i) 300,000 CHES Depositary Interests (CDIs) further to the Appendix 2A lodged today. The CDIs are in respect of options exercised.

NYR gives notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) that:

- 1 The CDIs were issued without disclosure to investors under Part 6D.2 of the Corporations Act.
- 1 As at the date of this notice, NYR has complied with:
 - (a) The provisions of Chapter 2M of the Corporations Act as they apply to NYR; and
 - (b) Section 674 and 674A of the Corporations Act.
- 2 As at the date of this notice, there is no information that is “excluded information” of the type referred to in sections 708A(7) and 708A(8) of the Corporations Act that is required to be disclosed by the Company under section 708A(6)(e) of the Corporations Act.

For and on behalf of the Board,

Yours faithfully,

A handwritten signature in black ink, appearing to read 'D. Franks'.

David Franks
Company Secretary

About Xolatryp™

Xolatryp (formerly known as NYR-BI03) is a small-molecule inhibitor of TRPC 3/6/7 channels designed to limit pathological Ca^{2+} entry, protect mitochondrial function, and reduce ischemia reperfusion injury associated with AMI.

[A Phase I clinical trial assessing the safety, tolerability, and pharmacokinetics has been completed](#), and a [Phase IIa clinical trial focusing on safety and preliminary efficacy](#) is scheduled to begin in the first quarter of CY2026. This upcoming study will enrol patients with acute myocardial infarction (AMI) who are undergoing primary percutaneous intervention (PCI).

– ENDS –

About Nyrada Inc.

Nyrada Inc. is a clinical-stage biotechnology company focused on the discovery and development of innovative small-molecule therapies, specifically targeting Transient Receptor Potential Canonical (TRPC) ion channels. The company's lead candidate, Xolatryp™, has shown efficacy in both cardioprotection and neuroprotection, and has just completed a first-in-human Phase I clinical trial. Nyrada Inc. (ARBN 625 401 818) is incorporated in Delaware, US, with limited liability for its stockholders.

www.nyrada.com

Authorised by John Moore, Non-Executive Chair, on behalf of the Board.

Investor & Media Enquiries:

Dimitri Burshtein

T: 0491 789 391

E: info@nyrada.com

Company Secretary:

David Franks

T: 02 8072 1400

E: David.Franks@automicgroup.com.au

Forward-Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not

certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement.